Market Cap: 27.1963B; Large Cap
P/E Ratio: 30.64; Fwd: 27.93
EPS (TTM): $2.3
Div. Yield: N/A

DXCMNASDAQ— DexCom Inc Price & Analysis

DexCom Inc

HEALTHCARE — MEDICAL DEVICES

$71.54

+$1.06+1.50%

Market Cap: 27.1963B; Large Cap
P/E Ratio: 30.64; Fwd: 27.93
EPS (TTM): $2.3
Div. Yield: N/A

Technical Summary

RSI (14)47.35Neutral

SMA (50)$71.71Bearish

SMA (200)$67.50Bullish

MACD0.4748Bearish

Bollinger$67.45 – $78.28Mid

Stochastic16.48Oversold

Theo Outlook

DexCom (DXCM) presents a bullish thesis with a $29.58B market cap, trailing P/E of 32.9, EPS of $2.33, and 15% YoY quarterly revenue growth on $4.82B TTM revenue, supported by 19.3% profit margins and 35.6% ROE. The stock trades at a premium reflecting strong demand for its continuous glucose monitoring systems in the expanding diabetes care market. Key catalysts include ongoing product innovation in CGM technology, international market expansion, and consistent earnings momentum with 92% YoY quarterly EPS growth, positioning DXCM for further adoption among healthcare providers and patients. Risks encompass regulatory hurdles in medical devices, intense competition from larger players, and macroeconomic pressures on healthcare spending; these are mitigated by DexCom's specialized focus, robust R&D pipeline, and high institutional ownership exceeding 103%. Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.

Theo Outlook

DexCom (DXCM) presents a bullish thesis with a $29.58B market cap, trailing P/E of 32.9, EPS of $2.33, and 15% YoY quarterly revenue growth on $4.82B TTM revenue, supported by 19.3% profit margins and 35.6% ROE. The stock trades at a premium reflecting strong demand for its continuous glucose monitoring systems in the expanding diabetes care market. Key catalysts include ongoing product innovation in CGM technology, international market expansion, and consistent earnings momentum with 92% YoY quarterly EPS growth, positioning DXCM for further adoption among healthcare providers and patients. Risks encompass regulatory hurdles in medical devices, intense competition from larger players, and macroeconomic pressures on healthcare spending; these are mitigated by DexCom's specialized focus, robust R&D pipeline, and high institutional ownership exceeding 103%. Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.

Company Overview

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.

Fundamental Snapshot

Revenue: 4.8179B
EBITDA: 1.2923B
Gross Profit: 2.9632B
Operating Margin: 21.4%
Profit Margin: 19.3%
ROE: 35.6%
Book Value: $7.66
Beta: 1.453
52-Wk High: $89.98
52-Wk Low: $54.11
Avg Volume: 2.782M
PEG Ratio: 1.332

Frequently Asked Questions

What is DexCom's business model?

DexCom develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It generates revenue primarily through sales of CGM hardware and related subscriptions, with TTM revenue of $4.82B and a 19.3% profit margin.

What are DexCom's main revenue sources?

Revenue comes from CGM system sales and recurring sensor subscriptions. TTM revenue reached $4.82B with 15% YoY quarterly growth, driven by domestic and international medical device sales in the healthcare sector.

What are DexCom's competitive advantages?

Trading Data

Open: $71.05
Previous Close: $70.48
Day Range: $69.79 – $71.85
Volume: 2.7828M
Shares Outstanding: 385.873M
Analyst Target: $85.75

Related Assets

Vertex Pharmaceuticals Inc

$477.36

+0.90%

ISRG

Intuitive Surgical Inc

$337.50

+1.65%

REGN

Regeneron Pharmaceuticals Inc

$656.01

+0.63%

Get Deeper Analysis

Ask Theo anything about DXCM — earnings, valuation, technicals, or portfolio fit.

Try HeyTheo Free

Company Overview

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.

Fundamental Snapshot

Revenue: 4.8179B
EBITDA: 1.2923B
Gross Profit: 2.9632B
Operating Margin: 21.4%
Profit Margin: 19.3%
ROE: 35.6%
Book Value: $7.66
Beta: 1.453
52-Wk High: $89.98
52-Wk Low: $54.11
Avg Volume: 2.782M
PEG Ratio: 1.332

Frequently Asked Questions

What is DexCom's business model?

DexCom develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It generates revenue primarily through sales of CGM hardware and related subscriptions, with TTM revenue of $4.82B and a 19.3% profit margin.

What are DexCom's main revenue sources?

Revenue comes from CGM system sales and recurring sensor subscriptions. TTM revenue reached $4.82B with 15% YoY quarterly growth, driven by domestic and international medical device sales in the healthcare sector.

What are DexCom's competitive advantages?

DexCom holds a leading position in CGM technology with strong brand recognition and a specialized focus on diabetes care. Its 35.6% ROE and 0.271% insider ownership underscore operational efficiency and innovation in medical devices.

What are the key risks for DXCM investors?

Key risks include regulatory approvals for medical devices, competition in healthcare, and macro headwinds affecting spending. The stock's 32.9 P/E and $29.58B market cap reflect these factors, offset by 103% institutional ownership.

What is the growth outlook for DXCM?

Growth outlook remains positive with 15% revenue growth, $2.33 EPS, and analyst target of $85.75. Expansion in CGM adoption and international markets support continued momentum, though no dividend is currently paid.